For years, viral vector manufacturing has advanced faster than the analytical frameworks used to measure it. While production platforms have scaled and diversified, the methods used to quantify viral vectors have remained fragmented, often varying across laboratories, organizations, and stages of development. This lack of alignment has created a persistent challenge: not just how to measure viral vectors, but how to measure them in a way that is consistent, comparable, and meaningful across the broader industry.
The publication of ISO 16921-2:2026 marks a turning point in how viral vector quantification is approached. Notably, the standard now includes LumaCyte’s Radiance® platform among the analytical methods recognized for viral vector measurement, reflecting a broader shift toward more precise and functionally relevant approaches. By establishing a global framework for measurement, the industry has taken a significant step toward aligning how viral titers are defined, assessed, and interpreted.
The Hidden Problem: Measurement Without Alignment
Much of the discussion around viral vector analytics has focused on the limitations of individual methods. Yet one of the most persistent challenges has been less about the methods themselves and more about the lack of standardization across them. Different organizations may use different assays, define titer in different ways, or apply varying thresholds for what constitutes acceptable performance. Even when similar methods are used, differences in execution can lead to variability in results.
This lack of alignment creates downstream consequences that extend well beyond the analytical lab. During process development, it can complicate the interpretation of results and make it difficult to compare conditions across experiments. In manufacturing, it can introduce uncertainty when transferring processes between sites or scaling production. In regulatory settings, it can lead to additional scrutiny as developers work to demonstrate that their measurements are both accurate and consistent.
Without a shared framework, even well-established methods can produce results that are difficult to reconcile across contexts. The challenge is not simply obtaining a measurement but ensuring that the measurement carries the same meaning wherever it is applied.
What ISO 16921-2 Changes
ISO 16921-2:2026 provides that shared framework. By defining approaches to viral vector quantification that can be applied across research, development, and manufacturing, the standard creates a common reference point for how viral titers are measured and interpreted. This does not eliminate the use of multiple analytical methods. Instead, it establishes a structure within which those methods can be evaluated, compared, and applied consistently.
One of the most important implications of this standard is the shift from method-specific results to standardized measurement concepts. Rather than relying on isolated assay outputs, organizations can begin to align around shared definitions of viral titer and performance. This alignment supports more consistent communication between stakeholders, including developers, contract manufacturers, and regulatory agencies.
The inclusion of advanced analytical approaches, including LumaCyte’s Radiance®, signals that the industry is expanding beyond traditional measurement paradigms. As viral vector applications have become more complex, the need for more precise and functionally relevant data has increased. ISO inclusion reflects that these advanced methods are not only viable, but appropriate within a globally recognized framework.
What More Precise Measurement Enables
Standardization alone does not solve every challenge in viral vector manufacturing, but it provides a foundation for more reliable and interpretable data. When measurements are both precise and consistently defined, they become more useful for decision-making across the lifecycle of a product.
In process development, more precise viral titer measurements allow teams to better understand how changes in conditions affect vector performance. Subtle differences that may have previously gone unnoticed can now be detected and addressed earlier, reducing the risk of variability later in the process. This leads to more efficient optimization and a clearer understanding of how upstream decisions influence downstream outcomes.
In manufacturing, standardized and precise measurements support greater consistency across batches and sites. When the same definitions and frameworks are applied, it becomes easier to identify true process variability versus analytical noise. This distinction is critical for maintaining control as production scales and for ensuring that product quality remains consistent over time.
More precise measurement also strengthens comparability assessments. As processes evolve from early development to commercial manufacturing, developers must demonstrate that changes do not impact product performance. Standardized measurement frameworks provide a more robust basis for these comparisons, reducing ambiguity and supporting more confident decision-making.
Implications for Cellular Therapy and Vaccine Development
The impact of ISO standardization extends across both cellular therapy and vaccine workflows. In cellular therapy, where dosing and transduction efficiency are closely tied to viral titer, improved measurement supports more consistent therapeutic dosing and performance. Clearer definitions of titer and function enable better alignment between process development, manufacturing, and clinical expectations.
In vaccine development and manufacturing, the ability to measure viral performance consistently becomes especially important as candidates move from early-stage research into large-scale production. Standardized and precise quantification supports more reliable evaluation of candidate formulations and helps ensure that manufacturing processes produce consistent results across batches and dosing is appropriate from a safety standpoint.
These benefits become even more important in scenarios that require rapid development and scale-up. During public health emergencies, the ability to generate consistent, interpretable data across organizations can influence how quickly a vaccine moves from development to distribution. Standardization reduces one layer of uncertainty, allowing teams to focus on optimizing performance and yields rather than reconciling measurement differences.
From Analytical Method to Industry Standard
The inclusion of LumaCyte’s Radiance® optical and fluidic force measurement platform within ISO 16921-2:2026 reflects a broader shift from isolated analytical methods to standardized, globally recognized measurement frameworks. This transition represents an important step toward greater alignment, improved reproducibility, and more meaningful data across the lifecycle of advanced therapies.
As cell and gene therapies and vaccine platforms continue to progress, the role of analytics will become increasingly central. Standardization does not eliminate complexity, but it provides a foundation for managing it more effectively. By aligning how viral vectors are measured, the industry is better positioned to build processes that are not only scalable, but also consistent, comparable, and ready for global application.
Learn more about how LumaCyte’s Radiance® platform is supporting standardized viral vector quantification at LumaCyte.com.
